Dashboard
Manage Tickers

EDIT Editas Medicine, Inc.

Nasdaq editasmedicine.com


$ 3.55 $ -0.19 (-5.07 %)    

Monday, 13-Oct-2025 16:07:45 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 601.77 nm (nm)
DIA $ 460.67 $ 2.46 (0.54 %)
SPY $ 662.65 nm (nm)
TLT $ 90.58 nm (nm)
GLD $ 378.25 $ 1.62 (0.43 %)
$ 3.72
$ 3.76
$ 3.52 x 1
$ 3.70 x 530
$ 3.53 - $ 3.84
$ 0.91 - $ 4.54
3,531,523
na
334.5M
$ 2.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-05-2025 01-01-1970 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-07-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 02-28-2024 12-31-2023 10-K
8 11-03-2023 09-30-2023 10-Q
9 08-02-2023 06-30-2023 10-Q
10 05-05-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-09-2021 09-30-2021 10-Q
17 08-05-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 02-26-2021 12-31-2020 10-K
20 11-06-2020 09-30-2020 10-Q
21 08-07-2020 06-30-2020 10-Q
22 05-08-2020 03-31-2020 10-Q
23 02-26-2020 12-31-2019 10-K
24 11-12-2019 09-30-2019 10-Q
25 08-07-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-01-2019 12-31-2018 10-K
28 11-08-2018 09-30-2018 10-Q
29 08-07-2018 06-30-2018 10-Q
30 05-04-2018 03-31-2018 10-Q
31 03-08-2018 12-31-2017 10-K
32 11-08-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-15-2017 03-31-2017 10-Q
35 03-03-2017 12-31-2016 10-K
36 11-09-2016 09-30-2016 10-Q
37 08-10-2016 06-30-2016 10-Q
38 05-13-2016 03-31-2016 10-Q
39 03-30-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

editas-medicine-reports-in-vivo-preclinical-proof-of-concept-data-for-edit-401-one-time-therapy-to-significantly-reduce-ldl-c-at-annual-esgct-congress-in-seville-spain
Editas Medicine Reports In Vivo Preclinica...
10/09/2025 15:03:59

editas-medicine-to-deliver-edit-401-oral-presentation-at-european-society-of-gene-and-cell-therapy-congress-october-710-2025-in-seville-spain
Editas Medicine To Deliver EDIT-401 Oral P...
10/06/2025 13:05:01

Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serio...

my-top-biotech-stock-picks-and-portfolio-strategy-for-the-next-3-10-years
My Top Biotech Stock Picks And Portfolio S...
09/18/2025 17:10:48

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of...

editas-medicine-stock-a-deep-dive-into-analyst-perspectives-4-ratings
Editas Medicine Stock: A Deep Dive Into An...
09/05/2025 12:01:59

hc-wainwright--co-reiterates-buy-on-editas-medicine-maintains-5-price-target
HC Wainwright & Co. Reiterates Buy on Edit...
09/05/2025 11:15:56

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Editas Medicine (NASDAQ:EDIT) with a Buy and maintains $5 pric...

wells-fargo-maintains-equal-weight-on-editas-medicine-raises-price-target-to-4
Wells Fargo Maintains Equal-Weight on Edit...
09/03/2025 13:04:50

Wells Fargo analyst Yanan Zhu maintains Editas Medicine (NASDAQ:EDIT) with a Equal-Weight and raises the price target from $...

editas-medicine-announces-edit-401-as-lead-in-vivo-candidate-with-90-ldl-c-reduction-and-human-proof-of-concept-by-2026
Editas Medicine Announces EDIT-401 As Lead...
09/02/2025 11:05:08

EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primatesEDIT-401 on track for human proof-of-concept ...

hc-wainwright--co-maintains-buy-on-editas-medicine-raises-price-target-to-5
HC Wainwright & Co. Maintains Buy on Edita...
08/15/2025 11:23:02

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Editas Medicine (NASDAQ:EDIT) with a Buy and raises the price t...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

baird-maintains-outperform-on-editas-medicine-raises-price-target-to-6
Baird Maintains Outperform on Editas Medic...
08/13/2025 12:02:29

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and raises the price target from $4 to $6.

editas-medicine-q2-eps-063-misses-038-estimate-sales-3578m-beat-1666m-estimate
Editas Medicine Q2 EPS $(0.63) Misses $(0....
08/12/2025 20:14:54

eli-lillys-13-billion-verve-deal-signals-confidence-in-gene-editing-space-analyst
Eli Lilly's $1.3 Billion Verve Deal Signal...
06/18/2025 17:59:21

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a...

editas-medicine-reports-58-mean-hbg12-promoter-editing-at-five-months-using-single-dose-tlnp-delivery-in-non-human-primates
Editas Medicine Reports 58% Mean HBG1/2 Pr...
06/12/2025 07:26:23

Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically ...

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
05/21/2025 12:07:32

editas-medicine-unveils-new-in-vivo-data-highlighting-potential-of-editas-gene-upregulation-strategy-in-hscs-at-american-society-of-gene-and-cell-therapy-annual-meeting
Editas Medicine Unveils New In Vivo Data H...
05/14/2025 11:07:14

baird-maintains-outperform-on-editas-medicine-lowers-price-target-to-4
Baird Maintains Outperform on Editas Medic...
05/13/2025 12:28:34

Baird analyst Joel Beatty maintains Editas Medicine (NASDAQ:EDIT) with a Outperform and lowers the price target from $8 to $4.

editas-medicine-shares-in-vivo-proof-of-concept-data-supporting-development-of-treatment-for-undisclosed-liver-target-in-poster-presentation-at-asgct-annual-meeting
Editas Medicine Shares In Vivo Proof Of Co...
05/13/2025 11:06:33

In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associa...

editas-medicine-q1-eps-092-misses-059-estimate-sales-466m-beat-70600k-estimate
Editas Medicine Q1 EPS $(0.92) Misses $(0....
05/12/2025 20:33:56

Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0...

editas-medicine-announces-us-court-of-appeals-of-federal-circuit-remands-crispr-patent-interference-to-patent-trial-and-appeal-board
Editas Medicine Announces U.S. Court Of Ap...
05/12/2025 20:06:29

Core News & Articles
Earnings Scheduled For May 12, 2025
05/12/2025 08:32:31

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION